To determine if these findings were also relevant to human NSCLC, we first examined differences in KRAS mutant isoform-specific survival outcomes from an internationally recruited cohort of advanced KRAS-mutant NSCLC patients, the RAS-Precision Medicine (RAS-PM) database. Here, KRAS is linked to non-small cell lung carcinoma.